Trial Profile
Phase II study of interleukin- 2 and bevacizumab in patients with progressive metastatic renal cell carcinoma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Interleukin-2 (Primary)
- Indications Carcinoma; Renal cancer
- Focus Therapeutic Use
- 24 Aug 2008 Actual patient number (6) added as reported by ClinicalTrials.gov.
- 24 Aug 2008 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 31 Jul 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.